Lexaria Bioscience Corp. (LEXX) stock

LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31

Financials through Q3 FY2026, quarter ended May 31, 2026Last filing: 10-Q on Jul 13, 2026Score 8/30

$4.44+0.26 (+6.22%)

Close on Nov 13, 2026Market cap $110.06MP/E –Yield –

Lexaria Bioscience EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Lexaria Bioscience has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Lexaria Bioscience's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Aug 3, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing